The purpose of this session is to discuss management of co-morbid viral and liver disease in patients living with hepatitis C. The experts will discuss their approach to hepatitis C treatment and post-treatment management in patients with concomitant HIV,
Disparities in health care are associated with worse health outcomes and occur globally in the context of broader inequity. There are many contributors to disparities across health systems, providers and patients, respectively. This session will introduce
In this session the possibilities for monitoring and treating hepatitis delta patients will be discussed. With new agents appearing there will be more possibilities for treating hepatitis delta patients with either suppressive or better curative therapies
This session will review the differential diagnosis of AKI, including a focus on AKI-HRS, and then review management strategies. There will be focus on terlipressin given its the publication of the recent NA RCT and its FDA approval, including indication
The purpose of this session is to discuss the unique challenges and opportunities for hepatitis C management in correctional facilities.
This session will discuss the current understanding, updates, and future directions related to immunology in ALD
Despite the anticipated FDA approval of the first MASH drug by the end of 2023, lifestyle interventions aiming at significant weight loss will remain cornerstone therapy for this disease. So far dietary interventions at large scale have failed to show sus
Recently, there has been increased interest in judicious use of IV albumin in patients with decompensated cirrhosis. On one hand, its use has been advocated as first line therapy for several indications. On the other hand, concerns about its unregulated u
There are known healthcare disparities within pediatric liver transplantation that impact access to care, listing, transplantation, and outcomes. This workshop is designed to discuss approaches and initiatives in patient advocacy to empower healthcare pro